HIV & trans women — hormones, ART, and the care you deserve.

For some trans women, starting HIV treatment brings a very personal worry: Will this affect my hormones or the changes that help me feel at home in my body? That question deserves a clear answer. You should be able to discuss both parts of your care without being judged or pressured to stop either medicine on your own.

The archived September 2024 federal HIV treatment guidance puts a number on the cost of that silence. In one study summarized by the guidelines, roughly 40% of participating trans women living with HIV reported not taking their antiretrovirals as directed because they were worried about interactions with their gender-affirming hormones — and fewer than half had ever raised that worry with a provider.5 That is not a story about anyone being careless. That is a story about a health system that made people choose between two things they needed and then never explained whether the choice was real.

For many commonly used regimens, treatment can be coordinated. Pharmacokinetic studies — in Bangkok, in Toronto, inside the DISCOVER and HPTN 083 trials — point in a consistent direction: modern integrase-based HIV treatment and modern PrEP can sit alongside feminizing hormone therapy without either one being sacrificed. This page walks through what those studies found, what genuinely does need watching, and the social and practical barriers that can also affect HIV prevention and care: housing, income, criminalization, violence, and clinics that never learned to use your name.

The numbers — and what they are actually measuring

Start with the honest version of the epidemiology. In a CDC meta-analysis pooling 88 U.S. studies conducted between 2006 and 2017, laboratory-confirmed HIV prevalence was 14.1% among trans women, 3.2% among trans men, and 9.2% among all trans people studied — against an adult U.S. prevalence of well under half a percent. These pooled estimates came from subsets of the included studies, not a nationally representative survey. Among Black participants, the pooled estimate was 44.2% across four studies, with a wide confidence interval, compared with 6.7% among white participants.1

CDC’s NHBS-Trans survey included 1,608 transgender women in seven U.S. urban areas during 2019–2020. Among those with valid HIV tests, 42% tested positive; 38% of survey participants reported a prior positive result. These measures should not simply be subtracted to count new diagnoses. The sample was not nationally representative. City estimates ranged from 21% in Seattle to 58% in Atlanta.2

The same study also documented barriers to care. Forty-four percent of the trans women interviewed had earned less than $10,000 in the previous year. Thirty-nine percent had experienced homelessness in the past 12 months. Forty percent reported severe food insecurity.2 Nearly two-thirds were living at or below the federal poverty level.1

Basic needs belong in HIV care

Poverty and unstable housing do not define anyone or explain every infection. In that survey, homelessness and severe food insecurity were associated with a lower likelihood of reported viral suppression (adjusted prevalence ratios 0.88 and 0.84). Comfort discussing gender-related needs with a provider was associated with suppression (aPR 1.17) and PrEP use (aPR 1.79). These observational associations support attention to care and basic needs, but do not prove causation.2

In CDC’s 2019 surveillance data, transgender people accounted for about 2% of HIV diagnoses among adults and adolescents, and roughly 93% of diagnoses among transgender people were among transgender women.1 By the end of 2022, 83% of transgender and nonbinary people with diagnosed HIV had received some HIV care, but only 67% were virally suppressed — well short of the 95% national target. HIV-related deaths among trans women rose 20% between 2018 and 2022.5

The global picture: what historical estimates show

In its 2024 thematic briefing, UNAIDS reported that new HIV infections among trans women rose 3% between 2010 and 2022, and that trans women's risk of acquiring HIV relative to the general adult population climbed from 11 times higher in 2010 to 20 times higher in 2022. Median HIV prevalence across 34 reporting countries was 9.2%, ranging as high as 58% in South Africa.3 Prevention service coverage sat at a median of 39% against a 95% target, and antiretroviral coverage at a median of 55%.3 As of June 2024, at least 16 countries criminalized gender identity or expression outright.3

The framing that best fits this data comes from Tonia Poteat, Andrea Radix, and colleagues, whose 2015 Lancet analysis calculated an odds ratio of 48.8 for HIV among trans women compared with other adults of reproductive age, with global prevalence around 19.1%.4 An updated 2021 meta-analysis of 98 studies covering 48,604 trans feminine people put standardized prevalence at 19.9%, with an odds ratio of 66.0.4 Poteat's team described trans feminine communities as carrying "some of the highest concentrated HIV epidemics in the world" — language that deliberately locates the problem in structural exclusion rather than in individual behavior.

Hormones and HIV medication — what the studies actually found

This is the section most people came for, so let us be precise. Feminizing hormone therapy typically means an estrogen — most often estradiol, given orally, transdermally, or by injection — usually combined with an anti-androgen such as spironolactone. The clinical goal in adults is to suppress testosterone below 50 ng/dL while holding serum estradiol in a range of roughly 100–200 pg/mL.5 This is not the same thing as postmenopausal hormone therapy in cisgender women — different doses, different formulations, different targets — and studies of one should never be quietly substituted for the other.

Both estradiol and several antiretrovirals are handled by overlapping liver enzyme systems, mainly CYP3A4, which is why the interaction question is a real pharmacological question and not a myth. But the answer depends enormously on which antiretrovirals.

The Toronto pilot: no statistically significant difference

Marina Loutfy's team in Toronto ran the study that most directly answers the exam-room question. They compared estradiol concentrations in trans women living with HIV who were virally suppressed on unboosted integrase inhibitor regimens — six on bictegravir/emtricitabine/tenofovir alafenamide, two on dolutegravir/abacavir/lamivudine — against trans women without HIV taking oral estradiol. Median dose in both groups was 4 mg. There was no significant difference in any estradiol measurement between the groups, and 73% were within the study’s estradiol target range at the four-hour sample.7 The sample was small — 15 people — and the authors were appropriately cautious. The result was reassuring for the specific combinations studied; 15 participants cannot rule out all interactions.

A Canadian chart-review cohort of 1,495 trans women found lower recorded feminizing-hormone prescribing among those with HIV (71.8%) than those without HIV (88.4%). Among hormone users with measurements, hormone levels did not differ significantly by HIV status. The study did not establish why prescribing differed; the gap alone does not prove deliberate withholding.7

The Bangkok studies: where a real interaction shows up

The iFACT studies out of Thailand tested the older regimens, and they did find something. In 20 trans women starting tenofovir disoproxil fumarate/emtricitabine plus efavirenz, estradiol exposure fell by roughly 28% (geometric mean ratio 0.72 for AUC), with the trough concentration dropping further.8 That is a genuine, measurable reduction — and it is worth knowing that efavirenz is the culprit, not HIV treatment as a category. Two details keep it in proportion: testosterone did not rise despite the estradiol drop, and 90% of participants had a viral load below 40 copies/mL after seven weeks.8 Efavirenz-based therapy is no longer first-line in U.S. guidelines, and commonly used unboosted integrase-based regimens have lower expected interaction potential.

Bone, heart, and clot risk — the other conversation

The guidelines flag a second set of considerations that has nothing to do with hormone levels and everything to do with long-term health. Antiretroviral choice should avoid adding unnecessary cardiovascular or bone risk on top of what hormone therapy may already contribute. Tenofovir disoproxil fumarate should be used with caution in anyone with osteoporosis risk factors, and DEXA timing should be individualized for trans people with HIV, considering age, fractures, hormone history, gonadectomy, and other risk factors (UCSF bone-health guidance). Where cardiovascular risk is elevated, transdermal estradiol may be the safer route because it carries a lower thromboembolism risk than oral dosing.5 Separately, ethinyl estradiol and conjugated equine estrogens are not recommended for gender-affirming hormone therapy at all, because of venous thromboembolism risk.6

One practical note the guidelines add: long-acting injectable antiretrovirals given intramuscularly in the buttock should not be injected into areas with gluteal implants or soft-tissue fillers.5 Tell whoever is giving the injection. It is a two-second conversation that prevents a real problem.

Integrated care — fewer barriers, coordinated treatment

The archived 2024 federal guidance contains a recommendation graded AII, which in that system means a strong recommendation supported by nonrandomized clinical trial or cohort data: HIV care for trans people should be delivered within a gender-affirming care model.5 This is not a comfort measure. It is a clinical intervention with outcome data behind it.

Three findings from that evidence base are worth stating plainly. Providers who use a person's chosen name and pronouns have patients who are more likely to be virally suppressed. Adherence to hormone therapy correlates with adherence to antiretroviral therapy — an association that does not prove one causes the other. And most importantly: making hormone access contingent on HIV treatment adherence is associated with a lower likelihood of viral suppression.5 Some clinics have used hormones as leverage — take your HIV meds and you get your estradiol. That association supports avoiding coercive care. If you have experienced this, ask for a collaborative plan or help finding another provider.

Integration also reduces the sheer logistical load. Co-locating HIV and gender-affirming services means fewer appointments, fewer waiting rooms where you have to brace yourself, and the possibility of coordinating blood tests. Routine HIV monitoring can ride along with the labs already being drawn for hormone titration.5 Peer navigation — support from people with shared experience — improves sustained viral suppression, and visibly trans staff make engagement more likely.5

Models like this exist and have been studied. Callen-Lorde Community Health Center in New York — one of the largest outpatient trans health practices in the country, serving more than 3,000 trans and gender-nonconforming patients — has been documented in the peer-reviewed literature as an integrated model where HIV testing is folded into the routine bloodwork already needed for hormone monitoring.5 Internationally, the Tangerine Clinic in Bangkok, a trans-led integrated gender-affirming and sexual health service, published data on 1,534 trans women showing that 34.2% had at least one hormone within the study’s target at baseline, while only 1.8% had both. Among the 302 participants with follow-up, 54.6% achieved or maintained at least one target concentration; this is not an improvement rate for all 1,534 participants.8 Brazil's response offers a scale example: São Paulo state created 30 new comprehensive services across 26 cities in a single year, and the Trans Amigas peer navigation programme was associated with 40% higher retention in care.3

PrEP — the evidence, the myths, and the new options

PrEP is HIV prevention medication for people who do not have HIV. For trans women it has a complicated history that is worth knowing, because the myths that circulate today are fossils of research decisions made fifteen years ago.

Why the early data looked bad

The iPrEx trial established that daily oral tenofovir/emtricitabine prevents HIV. When researchers went back — at the insistence of trans community advocates — and analyzed the 339 trans women in the study separately, the intention-to-treat result showed no benefit: 11 infections in the PrEP arm versus 10 in placebo.11 That headline traveled for years and did real damage.

The rest of the analysis almost never traveled with it. No trans woman who acquired HIV in the trial had detectable study drug at the infection visit. And no trans woman with drug levels consistent with four or more doses per week became infected. This was an observational drug-level analysis, not a recommendation to take PrEP only four days a week; use the prescribed regimen.11 The finding was not that PrEP fails in trans women. The analysis linked the lack of observed benefit to low measured drug exposure — plausibly because a study framed around "men who have sex with men" was not built to reach them, and because the hormone-interaction fear had no answers yet.

The pharmacokinetics have now been done

Several studies have since measured directly whether hormones and PrEP interfere with each other, and the pattern is consistent. Feminizing hormone therapy modestly lowers tenofovir in blood plasma — around 12–24% depending on the study — but does not meaningfully reduce the active intracellular forms of the drug, tenofovir diphosphate and emtricitabine triphosphate, which are what actually block HIV.913 A 2024 review of the literature concluded that PrEP efficacy "is expected to be maintained despite this interaction," and found no demonstrated interaction between hormones and either cabotegravir or tenofovir alafenamide.13

The studied PrEP combinations have generally been reassuring for hormone levels; this is not proof about every hormone formulation or medicine combination. The iFACT PrEP analysis found no change in estradiol or testosterone pharmacokinetics with tenofovir/emtricitabine, and the 2025 iFACT-3 study found no significant bidirectional interaction between hormones and oral emtricitabine/tenofovir alafenamide across blood, cellular, and rectal tissue compartments.9 Inside the DISCOVER trial, intracellular drug levels in trans women taking hormones were comparable to those in cisgender men who were not.12

Long-acting options, and a trial that got enrollment right

HPTN 083 tested injectable cabotegravir every two months against daily oral pills, and it deliberately set a minimum enrollment floor of 10% trans women — a design choice worth naming, because it is why usable data exist. The trial enrolled 570 trans women, 58% of whom reported using gender-affirming hormones. In the trans women specifically, there were 2 infections on cabotegravir versus 7 on oral tenofovir/emtricitabine, and cabotegravir drug concentrations did not differ by hormone use.14 In the overall trial, injectable cabotegravir reduced HIV acquisition by 66% compared with daily pills.14

Lenacapavir (Yeztugo) is a newer PrEP option, with initiation tablets plus injections and then injections every 26 weeks. HIV testing and on-time follow-up remain essential. PURPOSE 2 enrolled 3,265 people including trans women, trans men, and gender-nonbinary people who have sex with partners assigned male at birth. There were 2 infections in the lenacapavir group compared with 9 on daily oral tenofovir/emtricitabine — a 96% reduction against estimated background incidence and 89% against the daily pill. These are trial comparisons, not a guarantee for every person.15 The companion PURPOSE 1 trial in cisgender women in South Africa and Uganda recorded zero infections among 2,134 participants.15 The FDA approved lenacapavir for PrEP in June 2025, and CDC clinical guidance now includes twice-yearly lenacapavir as a strongly recommended PrEP option for people weighing at least 35 kg.15

The actual barriers

In the same seven-city surveillance program, a companion analysis of 902 transgender women without HIV found that 57% had recently discussed PrEP with a provider and 32% had used it. A usual source of care, insurance, transgender-specific care, and provider comfort were associated with PrEP use. These findings describe the study sample, not all trans women nationwide.^[2]

Gender-affirming surgery when you are living with HIV

HIV alone is not a contraindication to surgery. The team should assess your overall health, procedure, medicines, and recovery support. An unsuppressed viral load or low CD4 count calls for individual planning, not an automatic permanent refusal. Read the perioperative guidance.

The New York State Department of Health AIDS Institute guideline on perioperative care states it directly: HIV is not a contraindication to surgery. For a person on antiretroviral therapy with a viral load below 200 copies/mL and a CD4 count above 200, the recommendation — graded A2 — is to proceed exactly as for a patient without HIV. Avoid interrupting ART; if an interruption cannot be avoided, the surgical and HIV teams should coordinate it in advance.16

HIV status alone is not a reason to refuse surgery. Occupational transmission risk during surgery is extremely low, and standard precautions apply to every patient. U=U establishes zero risk for sexual transmission; after a blood exposure, staff should follow occupational-exposure protocols and obtain prompt PEP assessment rather than assume that the sexual-transmission evidence settles the question.^[23]16

The WPATH Standards of Care, Version 8, remains the reference document for gender-affirming surgical and hormonal care, including criteria, informed consent, and coordination between providers.17 Practical coordination matters: your HIV provider and your surgical team should be talking to each other about your regimen, your viral load, bone health if you are on tenofovir disoproxil fumarate, and how hormone dosing will be managed around the procedure. If nobody is convening that conversation, ask your HIV clinic's case manager to start it. That is squarely within their role.

Mental health — support, stress, and belonging

The 2022 U.S. Trans Survey, the largest survey of trans people in the United States, found that 78% of respondents reported lifetime suicidal thoughts and 40% reported a lifetime suicide attempt. It was a voluntary survey, not a representative estimate for every trans person.18 Those figures are devastating, and they are also frequently misread as though distress were an intrinsic feature of being trans. The survey documents strong associations with discrimination; it cannot establish every cause of distress.

Among respondents who had experienced no discrimination or harassment, 31% reported suicidal thoughts in the past year. Among those who had been verbally harassed, that rose to 50%. Among those who had been denied equal treatment, 53%. Among those who experienced both, 63%.18 These associations link discrimination with distress; they do not mean every trans person has the same experience. This is the gender minority stress framework in a single table: chronic external stressors — rejection, harassment, denial of care, the daily labor of anticipating all three — accumulate into measurable health outcomes.

The same survey found that trans women bore the highest HIV burden among respondents at 2.4%, more than three times the general U.S. prevalence of 0.3%, and that Black trans women reported the highest prevalence at 15.5%.18 UNAIDS reports a median of 49% of trans people experiencing stigma and discrimination across reporting countries, a median of 24% experiencing violence — reaching 69% in some countries — and a median of 10% avoiding health care altogether because of stigma.3 Avoiding care is a rational response to being mistreated in it. It is also a mechanism by which people go undiagnosed and untreated.

Two things are worth holding together. First, it is reasonable to ask a prospective therapist about their experience with trans clients and whether you feel respected — the WPATH and GLMA provider directories referenced in federal guidance are reasonable starting points for finding someone who does.5 Second, unmet basic needs are associated with HIV-care outcomes. In Ryan White program data, trans clients with unmet service needs were significantly more likely to have difficulty sticking with antiretroviral therapy (aPR 1.39) and to have a detectable viral load (aPR 1.47).5 Housing, food, and transportation are HIV interventions.

Sex work, survival economies, and criminalization

Many trans women trade sex for money, housing, food, or safety. This page will not treat that as a character flaw or a lapse in judgment, because the evidence does not support that framing.

Poteat and colleagues described sex work among trans women as arising from economic survival and, in many cases, from the need to fund gender-affirming care itself — in a context where trans women are pushed out of formal employment, education, and housing.4 When 44% of participants in this seven-urban-area U.S. survey earned under $10,000 in a year and 39% experienced homelessness, sex work is not an inexplicable choice.2 HIV prevalence among trans women sex workers was 27.3% in Poteat's Lancet analysis — higher than among trans women overall, and higher than among cisgender female sex workers — which reflects compounded exclusion, not compounded recklessness.4

What changes the numbers is law, and the public health consensus here is unusually clear. WHO's 2022 consolidated guidelines for key populations name decriminalization of sex work — removing all offences criminalizing sex workers, clients, and third parties — as a priority enabling intervention, alongside decriminalizing gender identity and expression and ending the police practice of treating condom possession as evidence of sex work.19 WHO cites modelling indicating that decriminalizing sex work could reduce new HIV infections among sex workers by 46% over ten years, and that eliminating sexual violence against sex workers could reduce them by 20%.19

Practical harm reduction still matters: PrEP, including long-acting options that do not require carrying pills; doxy-PEP where you meet CDC criteria; STI screening every three to six months at all sites of exposure; and knowing where the nearest clinic is that will not ask you to justify yourself.20 But none of that substitutes for the structural fix.

Partners, dating, and what U=U actually means

If you are living with HIV and taking antiretroviral therapy that keeps your viral load undetectable, you do not transmit HIV sexually. That is the substance of Undetectable = Untransmittable.

What that means in practice is that a mixed-status relationship has two independent layers of protection available. Your treatment keeps your viral load suppressed. PrEP is not needed to make U=U work. Your partner may still choose PrEP for personal reassurance or other exposures — daily pills, injectable cabotegravir every two months, or twice-yearly lenacapavir.15 Neither of you needs to organize your relationship around fear, and neither of you needs to accept the other's anxiety as a permanent condition.

Disclosure and transmission risk are different questions. Maintaining viral suppression prevents sexual HIV transmission, but legal duties vary; U=U is not a universal exemption from disclosure laws. Consider personal safety as well as legal advice when planning disclosure. Read Florida’s statutory requirements and why rights must not depend on viral load.

Two practical notes. Testing needs to follow anatomy, not gender: if you have receptive anal or oral sex, gonorrhea and chlamydia testing needs to be done at those sites, and site-specific screening is standard in CDC guidance.20 If you have had vaginoplasty, ask specifically how your surgical anatomy should be screened — the answer depends on the technique used, and a provider who has not thought about it should look it up rather than guess.

Care navigation — insurance, records, and getting the name right

September 2026 policy update: The challenge to federal restrictions on Ryan White-funded gender-affirming care reached a bench trial on September 23. The case record reviewed remains open; a trial does not itself mean a final ruling restored coverage. Ask your provider what is currently covered and under which funding source.^[24] Read the policy context and follow the case →

The Ryan White HIV/AIDS Program is the backbone of HIV care for people who are uninsured or underinsured in the United States, and it served 11,085 trans people in 2022 as reported in the archived 2024 federal guidance.5 Its outcomes for trans clients are decent but not equal: retention in care at 73.5% and viral suppression at 86.4%, compared with program-wide averages of 77.5% and 89.6%.5 Among trans clients with unstable housing, those figures fell to 67.5% and 73.6%.5 These data show an association with housing stability, not a ranking of housing against medical treatment.

One more structural note. Federal guidance recommends that clinics collect gender identity and sex assigned at birth as two separate questions, and that HIV surveillance systems do the same.5 A report that presents only male/female categories cannot show the full experience of transgender and nonbinary people. That does not establish how every individual was classified, and it should not be confused with a claim that all CDC surveillance omits gender identity. Poteat's team noted that laboratory-confirmed HIV data for trans women existed for only 15 countries at the time of their global review.4 Being counted is a prerequisite for being served.

Trans youth and trans elders

Two age groups are consistently underserved at opposite ends of the same continuum.

Younger trans people

Thirty-one percent of trans and nonbinary people newly diagnosed with HIV in 2022 were between 13 and 24 years old.5 That concentration in adolescence and young adulthood collides with the period when family rejection, school pushout, and housing instability are most acute, and when consent laws and insurance dependency make confidential care hardest to obtain. WHO's key populations guidelines explicitly identify lowering the age of consent for health services, and considering exceptions to standard consent policy, as enabling interventions.19 Lenacapavir's FDA approval covers adolescents weighing at least 35 kg, which matters for young people for whom carrying a daily pill bottle is itself a disclosure risk.15

Trans elders and long-term survivors

Trans women who have been living with HIV for decades are aging into questions the research is only starting to address: bone density after years of tenofovir disoproxil fumarate and hormone therapy, cardiovascular risk, and how hormone regimens should change with age. Bone-density screening should be individualized rather than assigned one age for every trans person; review fracture risk and hormone history (UCSF guidance). Clinical care also requires careful antiretroviral selection to avoid stacking cardiovascular and bone risk, with transdermal estradiol the lower-thromboembolism option where cardiovascular risk is elevated.5

The other thing trans elders carry is institutional memory — of the AIDS crisis, of buyers' clubs and street outreach and funerals, and of the fact that trans women were doing HIV work long before anyone funded it. Publications like POZ, Positively Aware, and TheBody have documented those histories in first person for decades, and they are where a lot of trans women first saw themselves described as people with futures.

Florida In Focus — the access map

Florida is one of the highest-burden HIV states in the country. The Florida Department of Health reported 4,725 new HIV diagnoses in 2023 and 128,497 people living with diagnosed HIV statewide at year-end. Among people newly diagnosed in 2023, 81% were linked to care within 30 days. Among all people living with diagnosed HIV statewide, 79% were in care and 70% had a suppressed viral load.21 The cited Florida report described the state’s diagnosis rate as third-highest among U.S. states for its comparison year; this is historical context, not a new 2026 ranking.21

Here is a gap worth knowing about if you live here: the state's HIV epidemiology report breaks its data down by male and female only, and does not report figures broken out by gender identity.21 This particular report does not show separate transgender outcomes or establish how each person was classified. More complete gender-identity reporting would help describe those needs, and it is a reasonable thing to raise with your county health department or local Ryan White planning council.

Florida’s restrictions and federal funding conditions can complicate coordinated care. Gender identity is not an exclusion in core Ryan White eligibility criteria, but enrollment and available services still depend on program rules. Ask about HIV treatment and hormone care separately, then request coordination. HIVMA/IDSA clinical guidance supports affirming care; clinical recommendations do not guarantee legal access or payment. See our Florida service guide for the current distinctions.5

Advocacy — who is doing the work

Trans communities deserve to be represented in research, from the questions asked to the outcomes measured. HPTN 083 deliberately enrolled trans women, making a dedicated analysis possible. A separate example also shows why current study status matters: ACTG A5403 “GET IT RiGHT” examined estradiol with HIV therapy, but its ClinicalTrials.gov record now lists the trial as terminated by the sponsor, with 93 participants enrolled. The record states that notice came in May 2025 and funding for planned retrospective pharmacokinetic testing was unavailable. Check the registry for the posted results and their limitations.7

The organizations are worth knowing by name. The TransLatin@ Coalition, founded in 2009 by Bamby Salcedo, organizes around identity documents, immigration, employment, housing, and health care for trans Latina immigrants — including the HOPE House transitional housing program, built on the premise that housing is HIV prevention.22 Positive Women's Network-USA organizes women living with HIV, including trans women, around policy, and the Sero Project works on HIV criminalization, which shapes disclosure decisions and safety in ways that rarely appear in clinical literature.

UNAIDS supplies the accountability metric for whether this work is being taken seriously: of 138 countries reporting, 47 do not engage trans people in policy processes at all.3 Where trans people are at the table — as in the Brazilian services expansion and the Trans Amigas navigation programme — outcomes improve.3 "Nothing about us without us" is not a slogan in this field. It is an implementation finding.

What you can do this week

If you take one thing from this page, take this: the interaction fear that keeps trans women from filling antiretroviral prescriptions is, for modern regimens, largely unfounded — and the fix for the parts that are real is a conversation, a lab draw, and sometimes a regimen switch. Not a sacrifice.

If you are living with HIV

• Name the hormone question out loud at your next appointment. In a study cited by the guidelines, about 40% of trans women with HIV reported adjusting their HIV medication over this worry and fewer than half told anyone.5 Ask directly: "Does my regimen affect my estradiol levels, and can we check?"
• Ask what class your antiretroviral is in. If it contains ritonavir, cobicistat, efavirenz, or etravirine, ask whether an unboosted integrase inhibitor is an option for you.5
• Ask for hormone levels to be monitored and titrated — that is what the guidelines recommend, not guesswork.5
• If anyone has ever conditioned your hormones on your HIV adherence, know that federal guidance identifies that practice as associated with worse viral suppression.5 You can ask for a different provider.

If you do not have HIV

• Ask about PrEP alongside your hormone regimen. Available interaction studies are reassuring, and the prescriber can check your specific combination.913
• Ask about all three delivery options — daily pills, cabotegravir every two months, or lenacapavir twice a year.15 If pills are a disclosure risk in your living situation, say so; that is a legitimate clinical consideration.
• Ask about doxy-PEP if you have had syphilis, chlamydia, or gonorrhea in the past year — CDC recommends providers offer it to trans women in that situation.20

For everyone

• Ask whether hormones and HIV care can happen in the same place. Integration is a graded recommendation, not a luxury request.5
• Get your chosen name into the chart, and ask that it be used at the front desk too.
• Ask about housing, food, and transportation assistance. These needs can affect staying in care. Ask which local assistance programs are available and what eligibility rules apply.25
• Find your people. Peer navigation and community connection show up repeatedly in the outcome data. They are not extras.5

You are not a statistic in an odds ratio. You are a person with a treatable condition, a body that deserves to look and feel like yours, and a need for care that addresses both parts of your health. You deserve clear answers, respectful care, and help navigating the barriers that remain.